Patents by Inventor Katerina Leftheris

Katerina Leftheris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF BETA-SECRETASE
    Publication number: 20140200223
    Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
    Type: Application
    Filed: December 18, 2013
    Publication date: July 17, 2014
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian Mckeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
  • Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
    Patent number: 8754076
    Abstract: Disclosed is a compound represented by Formula (Im1): or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof and methods of inhibiting 11?-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (Im1), or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Values for the variables in Formula (Im1) are defined herein.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: June 17, 2014
    Assignees: Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim, Boehringer-Ingelheim International GmbH
    Inventors: David A. Claremon, Frank Himmelsbach, Katerina Leftheris, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Linghang Zhuang
  • Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
    Patent number: 8673899
    Abstract: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: March 18, 2014
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: David A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Suresh B. Singh, Salvacion Cacatian, Wei Zhao
  • Inhibitors of beta-secretase
    Patent number: 8633212
    Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: January 21, 2014
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence W. Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
  • Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
    Patent number: 8598163
    Abstract: This invention relates to novel compounds of an 11 ?-HSD1 inhibitor disclosed herein, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11/3-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: December 3, 2013
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: David Claremon, Colin Tice, Suresh Singh, Yuanjie Ye, Katerina Leftheris, Linghang Zhuang
  • Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
    Patent number: 8592410
    Abstract: This invention relates to novel compounds of the Formula Il Ik, Im3, Im4, Im6-12, In3, In4, In6-12, lo3, lo4, lo6-12, Ip2, Ip4-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: November 26, 2013
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: David A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Yuanjie Ye, Suresh B. Singh, Frank Himmelsbach
  • Cyclic inhibitors of 11?-hydroxysteroid dehydrogenase 1
    Patent number: 8575156
    Abstract: Disclosed are compounds represented by Formula (I): or pharmaceutically acceptable salts, enantiomers or diastereomers thereof. Also disclosed are pharmaceutical compositions comprising the compounds of Formula (I) or pharmaceutically acceptable salts, enantiomers or diastereomers thereof and methods of inhibiting 11?-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Values for the variables in Formula (I) are defined herein.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: November 5, 2013
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Wei He, Gerard McGeehan, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Wei Zhao, Linghang Zhuang, Salvacion Cacatian, Katerina Leftheris
  • Cyclic inhibitors of 11?-hydroxysteroid dehydrogenase 1
    Patent number: 8569292
    Abstract: This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 ?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: October 29, 2013
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: David A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Suresh B. Singh, Salvacion Cacatian, Frank Himmelsbach, Matthias Eckhardt, Wei Zhao
  • SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE
    Publication number: 20130244993
    Abstract: The present invention relates to compounds defined by formula I: wherein the variables A1, A2, Cy1 Cy2, Cy3, E, R1a, R1b, R2, R3, n, and Q are as defined herein, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.
    Type: Application
    Filed: June 15, 2011
    Publication date: September 19, 2013
    Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, VITAE PHARMACEUTICALS, INC.
    Inventors: Katerina Leftheris, Linghang Zhuang, Colin M. Tice, Suresh B. Singh, Yuanjie Ye, Zhenrong Xu
  • Fused heterocyclic compounds useful as kinase modulators
    Patent number: 8476430
    Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation, wherein R1, R2, R3, R4, Q, A and B are as defined herein.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: July 2, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Katerina Leftheris, Andrew J. Tebben
  • Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1
    Publication number: 20130096108
    Abstract: Disclosed is a compound represented by Formula (Im1): or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof and methods of inhibiting 11?-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (Im1), or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Values for the variables in Formula (Im1) are defined herein.
    Type: Application
    Filed: October 5, 2012
    Publication date: April 18, 2013
    Inventors: Frank Himmelsbach, David A. Claremon, Linghang Zhuang, Katerina Leftheris, Zhenrong Xu, Colin M. Tice
  • Heterocyclic amide compounds useful as kinase inhibitors
    Patent number: 8404689
    Abstract: A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: March 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Jagabandhu Das, T. G. Murali Dhar, Alaric J. Dyckman, John Hynes, Katerina Leftheris, James Lin, Shuqun Lin
  • INHIBITORS OF BETA-SECRETASE
    Publication number: 20130053377
    Abstract: The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.
    Type: Application
    Filed: February 23, 2011
    Publication date: February 28, 2013
    Applicant: Vitae Pharmaceuticals, Inc.
    Inventors: Lawrence W. Dillard, Jing Yuan, Katerina Leftheris, Shankar Venkatraman, Guosheng Wu, Lanqi Jia, Zhenrong Xu, Salvacion Cacatian, Angel Morales-Ramos, Suresh Singh, Yajun Zheng
  • Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1
    Publication number: 20120232050
    Abstract: This invention relates to novel compounds of the Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (III). (III-A). (IIII-B). (III-C). (III-D), (III-E) (IV), (IV-A), (IV-B). (IV-C), (IV-D). (V), (V-A), (V-B), (V-C), (V-D), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Application
    Filed: June 30, 2010
    Publication date: September 13, 2012
    Applicant: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Katerina Leftheris, Linghang Zhuang, Colin M. Tice, Suresh B. Singh, Yuanjie Ye, Wei Zhao
  • CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE
    Publication number: 20120208804
    Abstract: This invention relates to substituted 1,3-oxazin-2-one compounds of the Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
    Type: Application
    Filed: June 10, 2010
    Publication date: August 16, 2012
    Applicant: VITAE PHARMACEUTICALS, INC.
    Inventors: David A. Claremon, Katerina Leftheris, Linghang Zhuang, Colin M. Tice, Suresh B. Singh, Yuanjie Ye
  • Cyclic inhibitors of 11?-hydroxysteroid dehydrogenase 1
    Patent number: 8242111
    Abstract: This invention relates to novel compounds of a structural formula selected from: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals, e.g., diabetes mellitus and obesity. Values for the variables in the structural formulas are provided herein. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 14, 2012
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Yuanjie Ye, Suresh B. Singh
  • CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20120178746
    Abstract: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 12, 2012
    Inventors: David A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Suresh B. Singh, Salvacion Cacatian, Wei Zhao
  • 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11?-hydroxysteroid dehydrogenase 1
    Patent number: 8202857
    Abstract: This invention relates to novel compounds of the Formula (I), (I*), (I**), I, Ia, Ib, Ic, Id, Ie, If, Ig, Il1-3, Im1-3, In1-3, or Io1-2, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: June 19, 2012
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Linghang Zhuang, Colin M. Tice, Suresh B. Singh, Yuanjie Ye, Wei Zhao, Katerina Leftheris
  • Fused heterocyclic compounds useful as kinase modulators
    Patent number: 8188272
    Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, [PLEASE INSERT CHEMICAL STRUCTURE HERE] (I) are useful as kinase modulators, including Btk modulation, wherein R1, R2, R4, Q, Y, A and D are as defined herein.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: May 29, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Katerina Leftheris, Andrew J. Tebben
  • Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
    Patent number: 8138178
    Abstract: Disclosed is a compound represented by Formula (Im1) or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof and methods of inhibiting 11?-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formulas (Im1), or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: March 20, 2012
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: David A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Suresh B. Singh, Salvacion Cacatian, Wei Zhao